2,646 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Csenge Advisory Group

Csenge Advisory Group bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,646 shares of the medical research company’s stock, valued at approximately $1,327,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Elyxium Wealth LLC raised its stake in shares of Thermo Fisher Scientific by 1.9% during the fourth quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock valued at $613,000 after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its position in shares of Thermo Fisher Scientific by 0.7% during the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares during the last quarter. Confluence Wealth Services Inc. grew its position in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Confluence Wealth Services Inc. now owns 4,292 shares of the medical research company’s stock worth $2,487,000 after acquiring an additional 22 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Thermo Fisher Scientific by 0.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,985 shares of the medical research company’s stock worth $2,311,000 after buying an additional 22 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $628.24 on Friday. The company has a 50 day moving average price of $539.33 and a two-hundred day moving average price of $508.86. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99. The stock has a market capitalization of $232.29 billion, a PE ratio of 33.79, a price-to-earnings-growth ratio of 2.50 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter last year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.11%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TMO shares. Royal Bank Of Canada boosted their price objective on Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research report on Friday, July 24th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Buying and Selling

In other news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This trade represents a 54.85% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 63,493 shares of company stock valued at $37,657,681. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.